We are honoring leaders who have made a measurable impact on healthcare in the past year and have a demonstrated track record in paving the way forward for others. These leaders have shown examples of innovation, passion and ingenuity.

There will be a COVID-19 surge this fall and winter. We have new treatments and vaccines. Will they ward off new subvariants?

Data from two preprint studies offer some inkling of what challenges the latest COVID-19 variant brings.

Moody's said it expects the physician staffing service and ASC operator to deplete its cash reserve by the end of 2023.

U.S. Drug Enforcement Administration agents have begun investigating digital therapeutics company Done Global Inc.’s practices for prescribing controlled substances, The Wall Street Journal reported. Federal authorities have shown growing interest in telehealth companies that prescribe stimulants like Adderall to treat attention-deficit hyperactivity disorder. Done’s primary competitor, Cerebral Inc., received a grand jury subpoena from the Justice Department for “possible violations” of the Controlled Substances Act in May.